Study Supports Use of Anthracyclines for Early, HER2-Negative Breast Cancer
July 29th 2016
Treatment with anthracyclines was proven to be beneficial for patients with high-risk, HER2-negative, early-stage breast cancer, according to a joint analysis of the Anthracyclines in Early Breast Cancer (ABC) trials.